V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

Chrome Holding Executive Compensation (FY24)

ME · Executive and director compensation, fiscal 2022 to 2024
Chief executive, fiscal 2024
◇
Anne Wojcicki
Latest say-on-pay support
=
August 26, 2024
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in one industry, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Chrome Holding brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 13, 2026Latest filing (8-K): August 27, 2024
5 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Chrome Holding brief$1,500Get the executive brief
Velarion Member, one year
197 figures on this page: 195 cited to the filing that reported them, 2 calculated from figures it prints. See the citations
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Anne Wojcicki: $62,920 → $7,363,723

Frequently asked questions

Answers drawn from the data on this page.
Who is Chrome Holding's chief executive and what were they paid?
Total compensation for Anne Wojcicki, Chief Executive Officer, came to $7,363,723 in fiscal 2024. Compared with the $62,920 reported for fiscal 2023, Wojcicki's total was up.
What was Chrome Holding's say-on-pay result?
Shareholders recorded 99.0% support for the say-on-pay proposal at the meeting held August 26, 2024 for fiscal 2024.
Which companies are in Chrome Holding's peer group?
The disclosed peer group includes Accolade, Inc., Adaptive Biotechnologies Corp., American Well Corp., Blueprint Medicines Corp. and BridgeBio Pharma, Inc., among others.
What is Chrome Holding's chief executive pay ratio?
For fiscal 2024, the company reported a chief executive pay ratio of 32:1, against median employee compensation of $227,981.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Anne Wojcicki
Chief Executive Officer
◇—◇◇———◇
Paul Johnson
Chief Operating Officer, Consumer
◇—◇◇◇—◇◇
Steven Schoch
Chief Financial Officer
◇—◇◇——◇◇
Kenneth Hillan
Chief Therapeutics Officer
◇—◇◇——◇◇
Kathy Hibbs
Chief Administrative Officer
◇—◇◇——◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Joseph Selsavage
Chief Financial and Accounting Officer
◇◇◇◇◇—◇◇
Anne Wojcicki
Chief Executive Officer
◇——————◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Anne Wojcicki
Chief Executive Officer
◇——◇———◇
Joseph Selsavage
Chief Financial and Accounting Officer
◇◇◇◇——◇◇
Kathy Hibbs
Former Chief Administrative Officer
Departed during or after this year
◇—◇◇——◇◇
William Richards
Head of Therapeutics Discovery
◇—◇◇——◇◇
Kenneth Hillan
Former Chief Therapeutics Officer
Departed during or after this year
◇——◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2023
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Anne WojcickiOPTION◇——◇—◇◇
Joseph SelsavageOPTION◇——◇—◇◇
Joseph SelsavageRSU◇——◇——◇
Kathy HibbsRSU◇——◇——◇
Kathy HibbsOPTION◇——◇—◇◇
William RichardsRSU◇——◇——◇
William RichardsOPTION◇——◇—◇◇
William RichardsOPTION◇——◇—◇◇
William RichardsRSU◇——◇——◇
William RichardsRSU◇——◇——◇
Fiscal 2022 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
William RichardsRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Joseph SelsavageRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Kathy HibbsRSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Anne WojcickiRSU◇◇——
Option◇—◇—
Option◇—◇—
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Anne Wojcicki
Chief Executive Officer · Terms as described in the company’s compensation discussion · citing a 2024 filing
Change-in-control multiple◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Excise tax treatment◇
Joseph Selsavage
Chief Financial and Accounting Officer · Terms as described in the company’s compensation discussion · citing a 2024 filing
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Excise tax treatment◇
William Richards
Head of Therapeutics Discovery · Terms as described in the company’s compensation discussion · citing a 2024 filing
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Excise tax treatment◇

Director compensation

What each non-employee director was paid.
Fiscal 2024
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Richard Scheller, Ph.D
◇◇———◇◇
Neal Mohan
◇◇————◇
Peter J. Taylor
◇◇————◇
Sandra Hernández, M.D
◇◇————◇
Roelof Botha
◇◇————◇
Valerie Montgomery Rice, M.D
◇◇————◇
Patrick Chung
◇◇————◇
Anne Wojcicki served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Equity is delivered as restricted stock units.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
  • Accolade, Inc. ACCD
  • Adaptive Biotechnologies Corp. ADPT
  • American Well Corp. AMWL
  • Blueprint Medicines Corp. BPMC
  • BridgeBio Pharma, Inc. BBIO
  • CareDx, Inc. CDNA
  • Cryoport, Inc. CYRX
  • Denali Therapeutics Inc. DNLI
  • Fulgent Genetics, Inc. FLGT
  • Guardant Health, Inc. GH
  • Health Catalyst, Inc. HCAT
  • Hims & Hers Health, Inc. HIMS
  • Invitae Corp. symbol not shown
  • iRhythm Technologies, Inc. IRTC
  • Myriad Genetics Inc. MYGN
  • Nanostring Technologies Inc. OSUR
  • Natera, Inc. NTRA
  • NeoGenomics Inc. NEO
  • Pacific Biosciences of California, Inc. PACB
  • Schrodinger, Inc. SDGR
  • Twist Bioscience Corp. TWST
  • Veracyte, Inc. VCYT

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2024August 26, 2024=◇◇◇
2022September 6, 2023=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Anne Wojcicki (Chief Executive Officer), FY2024 total compensation $7,363,723 (base salary $65,000) [exec_comp, SEC accession 0001140361-24-033309, filed 2024-07-16]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Chrome Holding files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Chrome Holding disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Chrome Holding sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Chrome Holding's disclosed peer group is defensible, who names Chrome Holding back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
197 figures on this page: 195 cited to the filing that reported them, 2 calculated from figures it prints.
195 cited to the filing
2 calculated from the filing

Documents cited

  1. 0001193125-24-207765
  2. 0001140361-24-033309
    Compensation Discussion and Analysis · DIRECTOR COMPENSATION · EXECUTIVE COMPENSATION TABLES · SUMMARY COMPENSATION TABLE
  3. 0001193125-23-232453
  4. 0001104659-22-080031
    SUMMARY COMPENSATION TABLE
  5. 0001104659-23-084282
    DETERMINATION OF EXECUTIVE COMPENSATION · SUMMARY COMPENSATION TABLE
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Chrome Holding executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/ME (accessed 2026).
Short form: data: Velarion

The Chrome Holding brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
5 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Chrome Holding and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Chrome Holding discloses

The companies named in ME's own disclosed peer group.

Accolade, Inc.Adaptive Biotechnologies Corp.American Well Corp.Blueprint Medicines Corp.BridgeBio Pharma, Inc.CareDx, Inc.Cryoport, Inc.Denali Therapeutics Inc.Fulgent Genetics, Inc.Guardant Health, Inc.Health Catalyst, Inc.Hims & Hers Health, Inc.iRhythm Technologies, Inc.Myriad Genetics Inc.Nanostring Technologies Inc.Natera, Inc.NeoGenomics Inc.Pacific Biosciences of California, Inc.Schrodinger, Inc.Twist Bioscience Corp.Veracyte, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy